- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- China planning agency OKs Shanghai Disney project
- China Eastern Airlines teams up with Alibaba
- Kinder Morgan expects to pay $4.40 annual dividend
- Mich. spammer gets 4 years in stock fraud scheme
- Icahn outbids Penn to open Fontainebleau auction
- Max Capital names new president of reinsurance ops
- Valspar fiscal 4th-quarter profit climbs
- Analog Devices 4Q earnings fall; 1Q outlook upbeat
- KBR to bid for part of $3B Air Force contract
Text Size 
NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. said Tuesday its profit rose 6 percent in the third quarter, as sales of its recently approved fever and pain treatment Caldolor were partly offset by costs to launch the drug.
Caldolor is an injectable form of ibuprofen that is intended for patients who are in the hospital and cannot take oral drugs. Cumberland launched Caldolor in the U.S. in September.
In the third quarter, Cumberland's profit rose to $1.3 million from $1.2 million. On a per-share basis, profit was unchanged at 7 cents.
Revenue climbed 58 percent to $13.6 million from $8.6 million, driven by Caldolor sales and greater use of Acetadote, an injectable drug intended to counteract overdoses of acetaminophen.
Analysts were expecting a smaller profit of a penny per share and $11.1 million in revenue, according to Thomson Reuters.
In midday trading, Cumberland stock advanced $1.09, or 8.7 percent, to $13.60. The company went public in August.
Cumberland said its sales and marketing expenses jumped to $6.1 million from $3.6 million a year ago, and general and administrative spending more than doubled to $2.5 million from $1.2 million.
Print
Email
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- CNBC’s Phil LeBeau took a test drive of GM’s flagship electric car. Here’s what he thought of the Volt.
- The energy company Power Efficiency is building tools that regulate the power electric motors use.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes